TEC-006

Indication

Moderate to severe inadequately controlled cancer-related pain.

Stage
Phase III

Location
Canada

Description
The objective of the trial is to evaluate the efficacy and safety of Tectin™ vs. placebo in patients with moderate to severe inadequately controlled cancer-related pain.  The trial is a multicentre, randomized, double-blind trial enrolling approximately 120 patients who will be administered Tectin™ or placebo subcutaneously for a treatment period of four days.  Efficacy and safety assessments will be conducted over a period of fifteen days or until pain returns.

The primary endpoint for the trial is a composite of pain outcome and quality of life measurements.  The secondary endpoints include the onset and duration of pain relief and reduction in the amount of other pain-relieving medications being used by patients.

Status
This trial is currently enrolling patients.

Further Information
For further details, please visit ClinicalTrials.gov.

For enrolment information, please call 1-888-866-8606.